

Turning Knowledge Into Opportunity



Your Partner In Technology Commercialization

Since 1989, Emergent Technologies Inc. (ETI), a life sciences venture capital firm, has specialized in converting innovative academic discoveries into high return ventures, creating novel technologies for industry leaders, and developing new opportunities for regional economies.

ETI portfolio companies are driving scientific advances in:

- Cancer and diabetes research
- Transplant medicine
- Vaccine research and development
- Medical and industrial diagnostics
- Chronic wound healing
- Specialized biochemicals, coatings and formulations

Bridging The Commercialization Gap Through Partnering

ETI is committed to bridging the gap between university or institutional technology transfer groups and companies in the life science industry. In doing so, we act as a commercialization partner both to the university and to the industry.

Building Commercial Success Through A Proven Process

We deliver success through careful selection of technologies that meet our proven criteria, and then pairing these technologies with our diverse team of technical business managers who drive further strategic development. Our unique business model involves rapidly accelerating the commercialization process through continuous market validation with industry partners and collaborators. The ETI portfolio team members work alongside the portfolio company chief scientist to bring multiple proofs of concept to industry leaders who partner with us to fund the commercialization of the technologies, leading to revenues for our investors.

Technology Selection

ETI searches for technologies that will transform industries. Selected technologies will have had previous research funding of at least \$5 million, will have a strong potential for intellectual property, and will ultimately yield over a \$500 million market opportunity for a commercialization partner. The most successful technologies will also exhibit potential for technical or business synergy with other ETI portfolio companies.

Research Institution Partnering

ETI serves as a commercialization partner to the university or research institution technology transfer group by forging and leveraging strategic industry relationships that profit both the research institution and the industry. Throughout the commercialization process, ETI provides revenue to the university by way of sponsored research, grant writing, industrial collaboration, and ultimately royalties or other equity returns when a product reaches the market.



"ETI converts university research into high-return ventures. We focus on commercializing breakthrough technologies with market-leading potential. Our portfolio companies drive or assist in the technology lifecycle from concept to prototype to market. For our partners, we provide cutting-edge developments that feed their R&D pipelines."



Strategic Industry Partnering

ETI assists the biotech, pharmaceutical, and medical industries in formulating strategies for commercializing promising technologies to expand market leadership, business revenue and competitive technology advantages. ETI provides access to breakthrough technology, collaborating with the partner to carry a technology through product development and market launch.

Economic Growth Through Technological Innovation

ETI strengthens local and regional economic competitiveness by promoting the efficient identification, management, development and commercialization of marketable research and technologies. Through our practice of forming biotech companies near to the university, we create local jobs and technology infrastructure, and also generate intellectual wealth and business revenue for universities, faculty, and the region as a whole.

Emergent Technologies, Inc. Portfolio Companies

AeonClad Coatings, LLC (www.aeonclad.com) Appian Labs, LLC (www.appianlabs.com) Auxano Biomedical, LLC (www.auxanobio.com) Beacon Sciences, LLC (www.beaconsciences.com) Choncept, LLC (www.choncept.com) Coradyn Biosystems, LLC (www.coradyn.com) Heparinex, LLC (www.heparinex.com) Hyalose, Ltd. (www.hyalose.com) MHC Biologics, LLC (www.mhcbiologics.com) Mimetic Solutions, LLC (www.mimeticsolutions.com) Pure Protein, LLC (www.pureproteinllc.com) Pure Transplant Solutions, LLC (www.pureproteinllc.com/transplant) Pure Vaccine Solutions, LLC (www.pureproteinllc.com/vaccine) Receptor Logic, Ltd. (www.receptorlogic.com) Reveal Sciences, LLC (www.revealsciences.com) Selenium, Ltd. (www.seleniumltd.com)

Emergent Technologies, Inc.

11412 Bee Caves Road Suite 300 Austin, Texas 78738 512.263.3232 www.etibio.com

